Skip to main content

Table 1 Incidence of ACLF in patients with different previous NUCs treatment experiences

From: Is HBV viral load at admission associated with development of acute-on-chronic liver failure in patients with acute decompensation of chronic hepatitis B related cirrhosis?

NUCs experiences HBV DNA ad-level
(IU/ml), n (%)
Log (HBV DNA), mean ± SD MELD scores, mean ± SD ACLF development, n (%)
<2000 ≥2000 n before admission after admission Total
naïve 26 (29.5) 62 (70.5) 4.55 ± 1.71 19.7 ± 8.9 88 22 (25.0) 11 (12.5) 33 (37.5)
maintained 8 (66.7) 4 (33.3) 2.27 ± 2.48 17.5 ± 9.9 12 2 (16.7) 3 (25.0) 5 (41.7)
interrupted 2 (18.2) 9 (81.8) 5.40 ± 1.90 15.4 ± 8.8 11 2 (18.2) 3 (27.3) 5 (45.5)
Total 36 (32.4) 75 (67.6) 4.39 ± 1.97 19.0 ± 9.0 111 26 (23.4) 17 (15.3) 43 (38.7)
  1. 1. NUCs experiences: naïve: antiviral treatment-naïve patients; maintained: patients with sustained long-term NUCs treatments till admission; interrupted: patients with interruption or discontinuation of antiviral treatment after long-term of NUCs therapies
  2. 2. HBV DNA ad-level <2000 IU/ml or ≥ 2000 IU/ml: Fisher’s exact test, P = 0.032
  3. 3. Log(HBV DNA) (logarithm of the serum HBV DNA ad-level): F = 10.150, P = 0.000
  4. 4. MELD scores (MELD scores at admission): F = 1.301, P = 0.276
  5. 5. ACLF development: Fisher’s exact test, P = 0.549; ACLF vs No-ACLF: χ2 = 0.309, P = 0.828; ACLF after admission vs No-ACLF: Fisher’s exact test, χ2 = 2.083, P = 0.353; ACLF before admission vs No-ACLF: Fisher’s exact test, P = 1.000